Phase I study of intrathecal 131-I-3F8 monoclonal antibody [iodine I 131 monoclonal antibody 3F8] in patients with GD2 positive leptomeningeal neoplasms

Trial Profile

Phase I study of intrathecal 131-I-3F8 monoclonal antibody [iodine I 131 monoclonal antibody 3F8] in patients with GD2 positive leptomeningeal neoplasms

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2013

At a glance

  • Drugs Monoclonal antibody 3F8 I-131 (Primary) ; Monoclonal antibody 3F8 I-131 (Primary)
  • Indications Cancer; Carcinomatous meningitis; CNS cancer; Glioma; Malignant melanoma; Medulloblastoma; Neuroblastoma; Retinoblastoma; Sarcoma; Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top